Partial Remission of Phospholipase A2 Receptor (PLA2R) Antibody-Positive Membranous Nephropathy Refractory to Rituximab with Use of Obinutuzumab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0711; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Cyclosporine was started at 100 mg twice daily, but was reduced to 75 mg twice daily due to worsening hypertension requiring escalation of antihypertensive therapy. CD19 count remained suppressed throughout the whole course. Discussion This case highlights obinutuzumab as a potential salvage therapy for rituximab-refractory PLA2R-positive PMN and supports emerging evidence for alternative anti-CD20 therapies in resistant disease."
Clinical • Cardiovascular • Fibrosis • Glomerulonephritis • Hypertension • Immunology • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases • Tuberculosis
|
|
Pedro A. Lopez-Gutierrez; Wajeeha Saeed; Sandy F. Aguilar; Mohamed Abdali; Pablo Garcia
|